INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)
Clinical trial NCT03424122 · COMPLETED
Trial details
- NCT number
- NCT03424122
- Sponsor
- Incyte Corporation
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-07-02
- Primary completion
- 2022-06-27
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.